Starpharma (ASX:SPL) has announced the opening of the MD Anderson Cancer Center as another site for the phase one trial of AZD0466 - AstraZeneca’s first DEP product.
The University of Texas MD Anderson Cancer Center (MDACC) is a respected cancer hospital based in Houston. It is the largest cancer centre in the US and is devoted exclusively to cancer patient care, research, education and prevention.
AZD0466 is an optimised nanomedicine formulation of AstraZeneca’s novel dual Bcl2/xL inhibitor that utilises Starpharma’s DEP technology. The development of AZD0466 is being progressed through a multi-product licence under which Starpharma is eligible to receive development, launch and sales milestones.
Dr Jackie Fairley, Starpharma CEO, said, “We’re pleased to see the ongoing progress of the AZD0466 trial. It is exciting to have this highly novel DEP®-based product being made available to patients at this leading international cancer center.”